Doc Aslam booted forever from FDA drug dealings
Published Date: 9/25/2026
Notice
Summary
The FDA has permanently banned Dr. Naveed Aslam from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on September 25, 2026. Dr. Aslam can apply to end this ban anytime, but it won’t be easy or quick.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 4 costs, 0 mixed.
Permanent ban on Dr. Aslam
Dr. Naveed Aslam is permanently barred from providing services in any capacity to any person that has an approved or pending drug product application. The debarment is effective September 25, 2026, following his federal conviction on November 17, 2025.
Employers face penalties if they hire him
Any person with an approved or pending drug product application who knowingly employs, retains as a consultant or contractor, or otherwise uses Dr. Aslam's services during his debarment will be subject to civil money penalties under section 307(a)(6) of the FD&C Act. The prohibition and penalty exposure are effective September 25, 2026.
Dr. Aslam personally liable for penalties if he works
If Dr. Aslam provides services in any capacity to a person with an approved or pending drug product application during his debarment, he will be subject to civil money penalties under section 307(a)(7) of the FD&C Act. This penalty exposure applies during the debarment period that is effective September 25, 2026.
FDA will not review his ANDA submissions
During his debarment, the FDA will not accept or review any abbreviated new drug application (ANDA) submitted by Dr. Aslam, except when submitted in connection with an audit under section 306(c)(1)(B) of the FD&C Act. This restriction is effective September 25, 2026.
Can apply to end debarment; application posted publicly
Dr. Aslam may apply at any time for special termination of debarment under section 306(d)(4) of the FD&C Act. Applications submitted electronically to https://www.regulations.gov will be posted publicly, while paper submissions can include a confidential copy to keep certain information from public posting.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19704, Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide for companies making robot-assisted surgical devices, showing how to get their products approved before selling. If you’re in the biz, now’s the time to check it out and send your feedback by November 24, 2026. This guide aims to make the approval process clearer and smoother, potentially saving time and money down the road.
2026-19655, Jeffrey Thies: Final Debarment Order
Jeffrey Thies is banned for 10 years from importing any drugs into the U.S. because he was convicted of trafficking fake drugs. He didn’t respond to the FDA’s notice, so the ban started on September 25, 2026. He can apply to end the ban anytime, but until then, no drug imports for him!
Previous / Next Documents
Previous: 2026-19651, 60-Day Notice of Proposed Information Collection: 2027 Rental Housing Finance Survey
HUD is asking for approval to collect updated info in the 2027 Rental Housing Finance Survey, which looks at how rental homes are financed across the U.S. Property owners and managers might be asked to share details about mortgages and finances. Comments on this plan are open until November 24, 2026, so now’s the time to speak up!
Next: 2026-19655, Jeffrey Thies: Final Debarment Order
Jeffrey Thies is banned for 10 years from importing any drugs into the U.S. because he was convicted of trafficking fake drugs. He didn’t respond to the FDA’s notice, so the ban started on September 25, 2026. He can apply to end the ban anytime, but until then, no drug imports for him!